

SOM Biotech and Inorgen sign a co-development agreement on drug repositioning

Barcelona, February 3rd 2016.

SOM Biotech, a clinical-stage biopharmaceutical company established in Barcelona (Spain), and the Anglo-Italian biotech accelerator **Inorgen** established in London (UK) and Milan (Italy) have successfully reached an agreement to co-develop drug repositioning programs focused mainly on rare diseases. Repositioning (new activities for already known drugs) and rare diseases (low prevalence diseases) are two concepts widely known by both companies. By combining these concepts, costs and time needed to bring the drug onto the market is reduced. Safety risks are also lowered.

The agreement has the determination to join the know-how of both companies with the aim to identify new repurposing candidates, either through internal discovery tools or through external in-licensing and co-development. The extensive network of Inorgen with academia, research institutions and biotech companies, along with the discovery tools and development activities of SOM Biotech makes a unique and promising way to accelerate new treatments from discovery to clinical stage.

About Inorgen

Inorgen (www.inorgen.com) is a biotech accelerator established in 2013 based in the UK and in Italy. The company is specialized in identifying promising compounds from new molecular entities and repurposed drugs and partner with academia, research institutions and biotech companies based globally. Compounds are incubated, de-risked and developed as drug candidates for pre-clinical and/or clinical programs. Successful projects become the assets for the creation of stand-alone companies partnering with financial investors, biopharma companies or seeking dedicated grants and loans.

About SOM Biotech

SOM Biotech Ltd. (www.sombiotech.com) is a biopharmaceutical company based within the Barcelona Science Park, founded in 2009. The company's mission is to conduct drug identification, experimental demonstration, intellectual protection, clinical proof-of-concept and licensing of new applications and medical indications for previously marketed drugs (repositioning or repurposing). Identification is performed using a proprietary computational virtual screening platform. SOM has an extensive pipeline of products under development ranging from rare diseases (TTR amyloidosis, Huntington's disease and glioblastoma multiforme) to other therapeutic areas (Alzheimer's disease and benign prostatic hypertrophy). To date, SOM Biotech has filed seven patents for new medical indications and conducts its work in collaboration with leading pharmaceutical companies.